Hydroxyapatite News and Research

RSS

Tiny lumps of calcium phosphate may trigger age-related macular degeneration

New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness.

20 Jan 2015

Amedica's CASCADE data shows silicon nitride spacers are comparable to hollow-body PEEK spacers

Amedica Corporation, a biomaterial company that develops and commercializes silicon nitride ceramics, today released the results of its CASCADE study, a blinded, randomized clinical trial that compared outcomes of spinal fusion surgery between its composite silicon nitride spacers manufactured with a central core of cancellous structured ceramic (CsC), to the gold standard, i.e., PEEK (polyether ether ketone plastic) spacers filled with bone autograft.

6 Jan 2015

Lucideon announces successful development of bioceramics for bone repair

As a partner in the EU-funded Bio-Bone project (Bioceramics for Bone Repair) Lucideon is pleased to announce that the pan-European consortium has successfully developed phosphate-glasses (p-glasses) with biomaterial properties for bone repair.

From Lucideon 3 Oct 2014

$Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis$

Raloxifene: FDA approved treatment for decreasing fracture risk in osteoporosis

Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis.

30 Aug 2014

"Self-fitting" material precisely fills bone defects and acts as scaffold for new bone growth

Injuries, birth defects (such as cleft palates) or surgery to remove a tumor can create gaps in bone that are too large to heal naturally. And when they occur in the head, face or jaw, these bone defects can dramatically alter a person's appearance.

13 Aug 2014

RTI Surgical launches 2 new biological solutions at AAOS annual meeting in New Orleans

RTI Surgical Inc., a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans this week. NanOss Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3™ Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.

12 Mar 2014

New surface treatment processes for orthopaedic and dental implants to reduce risk of infection

Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.

19 Dec 2013

White paper discusses the effects of particle shape and size on the properties of medical materials

Ceram, the international materials technology company, has published a new white paper for the medical devices industry, ‘The Effects of Particle Size Distribution on the Properties of Medical Materials’.

3 Dec 2013

Sea coral could soon be used in bone grafting procedures

Sea coral could soon be used more extensively in bone grafting procedures thanks to new research that has refined the material's properties and made it more compatible with natural bone.

29 Nov 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Fluoride in drinking water and oral-care products prevents tooth decay, shows research

In an advance toward solving a 50-year-old mystery, scientists are reporting new evidence on how the fluoride in drinking water, toothpastes, mouth rinses and other oral-care products prevents tooth decay.

2 May 2013

Research identifies important role of zinc in kidney stone formation

Kidney stones usually make their presence known suddenly, often sending a person to the hospital in excruciating pain. Each year in the U.S. more than a million people seek medical attention for kidney stones, technically called nephrolithiasis.

8 Apr 2013

VENADO bone graft systems launched by K2M

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company’s U.S. biologics offering with the launch of the VENADO® Foam Strips and VENADO Granules Bone Graft Systems.

27 Mar 2013

North Carolina researchers successfully coat polymer implants with YSZ bioactive film

Researchers from North Carolina State University have for the first time successfully coated polymer implants with a bioactive film. The discovery should improve the success rate of such implants - which are often used in spinal surgeries.

20 Feb 2013

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

18 Jan 2013

Regulatory approval service for hydroxyapatite users and manufacturers in the medical device industry launched by Ceram

Ceram, the international materials technology company, has launched a Regulatory Approval Service, designed to help hydroxyapatite users and manufacturers in the medical device industry gain FDA acceptance of their 510(k) submission.

10 Oct 2012

Hydroxyapatite coating on bone grafts may increase likelihood of successful implants

Coating a bone graft with an inorganic compound found in bones and teeth may significantly increase the likelihood of a successful implant, according to Penn State researchers.

27 Sep 2012

FDA acceptance achieved by Greatbatch Medical thanks to help from Ceram

Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.

21 Aug 2012